Research information only. PrecisePep is an educational library. It is not medical advice and is not intended to assist, encourage or enable self-administration. The compounds documented here are research chemicals — most are not approved for human use. Read the full disclaimer.
PrecisePep/Peptide Library/Epitalon
Longevity & Circadian
Epithalon · Ala-Glu-Asp-Gly · AEDG · Epithalamin (peptide extract)
A four-residue pineal bioregulator with the boldest claim in the field — telomerase induction and telomere elongation in human somatic cells — resting almost entirely on one Russian research programme.
Epitalon is the compound where the gap between claim and evidence is widest. It is a synthetic tetrapeptide derived from Epithalamin, a bovine pineal gland extract developed in the Soviet Union by Vladimir Khavinson's group at the St Petersburg Institute of Bioregulation and Gerontology, who have pursued "peptide bioregulator" gerontology for decades.
The headline finding is real and remarkable: treatment of normal human diploid fibroblasts with AEDG induced expression of the telomerase catalytic subunit, telomerase activity, and telomere elongation — reported at around 33% on average — allowing cells to divide beyond the Hayflick limit.[1] Independent work has since reported telomere lengthening in human cell lines through telomerase upregulation or ALT activity.[2]
The longevity claims are a different matter. Khavinson's group reported reduced mortality and extended lifespan in animals, and human observational work in elderly cohorts. Those studies are decades old, predominantly from one institute, mostly published domestically, and largely unreplicated by independent groups to modern standards. A 2025 review has since consolidated the field.[3]
Telomerase reactivation is one of the defining features of most human cancers — it is how malignant cells escape replicative senescence. The Hayflick limit is a tumour-suppressive mechanism, not merely an inconvenience of ageing. Any compound proposed to induce telomerase in somatic cells raises the corresponding question directly, and no study has answered it for chronic human use.
Telomerase induction. The central claim: AEDG induces expression of hTERT, the telomerase catalytic subunit, restoring telomerase activity in somatic cells that normally lack it and permitting telomere elongation.[1][2]
Epigenetic and gene-expression effects. The peptide-bioregulator hypothesis holds that short peptides interact directly with DNA and histone proteins, modulating gene expression in a tissue-specific manner. This is the theoretical framework underlying the entire Khavinson programme, and it remains a minority position in mainstream molecular biology.
Pineal function and melatonin restoration. Epitalon derives from pineal extract and is reported to restore age-related decline in melatonin secretion and normalise circadian rhythm — the basis for its sleep-related claims and, arguably, the most plausible of them.
Antioxidant and anti-inflammatory activity. Reported reduction of lipid peroxidation and oxidative damage markers.
Neuroendocrine-immune normalisation. The broader claim from the source programme: that pineal bioregulators restore coordination across the neuroendocrine and immune axes with age. Broad, difficult to test, and correspondingly difficult to falsify.
Effects that have been reported. A study-tier entry means a result was published — not that the effect is established, reproducible, or transferable from a rodent to a person.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Treatment of normal human diploid fibroblasts with AEDG induced hTERT expression, telomerase activity, and telomere elongation — reported at roughly 33% on average — with cells overcoming the division limit.
More recent work reports Epitalon increasing telomere length in human cell lines through telomerase upregulation or alternative lengthening of telomeres — independent corroboration of the core in vitro finding.
Reported normalisation of age-related decline in nocturnal melatonin and restoration of circadian rhythmicity in animal and human work from the source programme.
Khavinson group studies report reduced tumour incidence and extended mean lifespan in rodents. Old studies, single-programme, limited independent replication.
Long-running observational studies in elderly Russian cohorts reported improved physiological markers and reduced mortality with repeated peptide bioregulator courses. Not randomised or blinded to modern standards.
A 2025 review provides an overview of Epitalon as a highly bioactive pineal tetrapeptide, summarising the accumulated evidence and its limitations.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
The claim that drives all use. It rests on cell-culture telomere data plus old animal work plus weak human observational studies. No controlled human trial has assessed any longevity endpoint. This is the largest inferential leap documented anywhere on this site.
The most defensible human hypothesis, given the pineal origin and melatonin mechanism. Still unproven in controlled trials.
From the neuroendocrine-immune normalisation framework. Broad and difficult to test.
Extrapolated from reported antioxidant activity.
The counter-hypothesis to the entire premise. Telomerase reactivation is a near-universal feature of malignancy, and replicative senescence is tumour-suppressive. That Khavinson-group animal work reports reduced tumour incidence is the direct counter-argument, and it comes from the same programme making the primary claim.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
The most consistent community report, and the one best aligned with the melatonin mechanism.
Reported and consistent with a circadian mechanism.
Broadly reported, unmeasurable, and the type of claim most vulnerable to expectation effects — particularly for a compound purchased explicitly as an anti-ageing agent.
Occasionally reported over longer courses.
Some users purchase commercial telomere-length testing before and after. Consumer telomere assays have substantial measurement variability, and the effect sizes being claimed sit within that noise.
Common — unsurprising for a compound whose claimed benefits are, by their nature, not something a person can feel.
Adverse effects, contraindications and unknowns. The grey-market tier is where under-reporting is worst: uncontrolled use produces no systematic safety surveillance at all, so absence of a reported harm is not evidence of safety.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
The Khavinson literature consistently reports an absence of toxicity across animal and human work. Same-programme reporting, and the human work is not blinded.
No regulatory review, no independent pharmacovigilance, no controlled trial safety dataset.
The relationship between telomerase activity and malignancy is one of the best-established facts in cancer biology. Any telomerase-inducing agent inherits that question whether or not a study has looked for it.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
The specific concern: telomerase induction in a cell that has already accumulated oncogenic mutations removes a barrier to its expansion. Nobody using this compound is screened for that, and no study has examined it.
The pineal gland does more than melatonin. Chronic pharmacological manipulation of pineal signalling has no characterisation in humans.
A compound acting on circadian machinery, dosed at an arbitrary time, could plausibly shift rhythm in an unwanted direction.
Uncharacterised. Notable given the demographic most likely to use a longevity compound is also the demographic with the highest baseline cancer incidence.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Commonly reported, consistent with a melatonin-related mechanism.
Reported; the origin of the evening-dosing convention.
Mild and infrequently reported.
Reflects short courses (typically 10–20 days, once or twice a year) and low total exposure as much as it reflects any safety property.
Figures below are documented, not recommended. Study ranges come from published protocols in the stated model; grey-market ranges are what the research community reports using and carry no safety validation of any kind.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Khavinson-group human work used defined short courses of peptide bioregulators — typically repeated once or twice yearly rather than continuously — administered by injection or intranasally.
The telomerase findings come from cell culture at defined concentrations. Nothing connects those to a systemic human dose.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
The dosing structure that both the source programme and community practice converge on, and the one that limits cumulative exposure to a telomerase-inducing agent. If the oncological concern is real, infrequent short courses are the risk-minimising approach.
Aligns with the pineal and melatonin mechanism. Physiologically coherent.
Used in some Russian work. No comparative bioavailability data.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
The schedule in the Gold Standard protocol — with the stated rationale of stimulating telomere lengthening, reducing oxidative stress, resetting immune strength, repairing melatonin production and restoring circadian rhythm. Reproduced as circulated; the claims attached to it far exceed the evidence.
A higher-dose short-course variant in circulation.
Another circulating course structure.
Reported occasionally and inconsistent with every course-based precedent, including the practice of the source programme itself. The scenario with the highest cumulative telomerase exposure.
| Course | Dose | Duration | Repeat interval |
|---|---|---|---|
| Gold Standard Protocol | 1 mg daily | 10 days | Twice yearly |
| Higher-dose short course | 5 – 10 mg daily | 10 – 20 days | Annually |
| Spaced course | 10 mg | Every 3rd day × 3 weeks | Annually |
| Continuous (discouraged) | 1 – 5 mg daily | Ongoing | — |
Combination effects. Almost no peptide combination has been studied as a combination in humans; stack logic is overwhelmingly mechanistic inference and community practice. Each linked compound has its own page.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
No study has combined Epitalon with another peptide.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
The circulating sequencing places Epitalon last in the mitochondrial and longevity sequence — structural repair, then metabolic function, then the telomere and circadian layer. The ordering is narrative rather than mechanistic; the three compounds do not act on a shared pathway.
Redundant rather than synergistic if the mechanism is melatonin restoration — administering melatonin directly achieves the endpoint without the telomerase question.
Improved sleep architecture would in principle support the nocturnal GH pulse that secretagogues target. Indirect and speculative.
Combining a telomerase inducer with pro-angiogenic peptides and GH/IGF-1 elevation stacks several independent proliferative pressures. No community protocol acknowledges this combination as a category of risk.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Added after SS-31 and MOTS-c in the circulating protocol.
Common grouping, no interaction rationale.
Whole schedules — dosing, titration, cycle length, and off-time — as documented in trials, as proposed from mechanism, and as circulated in the research community. Reproduced for study and comparison only.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Short repeated courses over years in elderly cohorts, with physiological and mortality endpoints. Long-running, observational, single-institute.
Treat human diploid fibroblasts at defined concentrations, assay hTERT expression, telomerase activity and telomere length, and measure population doublings against the Hayflick limit.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Minimises cumulative exposure to a telomerase-inducing agent while matching the course structure used by the source programme.
If the telomerase mechanism is real, the coherent precaution is knowing there is no existing malignancy before inducing telomerase. This is the most important practical implication of the mechanism and it appears in no community protocol.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Positioned as the final addition to the mitochondrial repair sequence, after SS-31 and MOTS-c. Reproduced as circulated.
Placed in the yearly rather than quarterly or weekly tier of the phased matrix, reflecting the course-based structure.
Epitalon is sold on the largest claim in this library — that it extends lifespan — supported by the smallest and most closed evidence base. It also carries a mechanistic tension that is rarely stated: the specific thing it is claimed to do is the specific thing nearly every cancer cell already does.
Epitalon is not approved anywhere and has no controlled Western trial for any indication. The supporting literature is almost entirely from one research programme in St Petersburg, spanning several decades, largely published in Russian-language journals or in translation, and substantially unreplicated by independent groups. That is a different situation from Semax, which at least holds a formal Russian registration; Epitalon does not.
Pathophysiology
Telomeres shorten with each cell division, and critically short telomeres trigger senescence or apoptosis. Telomerase rebuilds them. Most somatic cells switch telomerase off after development, which limits their replicative lifespan.
Mechanistic rationale
Epitalon is claimed to activate telomerase and lengthen telomeres, which is the core of the longevity argument. Telomerase reactivation is also one of the most consistent features of cancer — the large majority of human tumours reactivate it, and it is precisely what allows a malignant clone to divide indefinitely. The replicative limit that telomere shortening imposes is a tumour-suppressive mechanism, not merely an inconvenience of ageing. A compound proposed to lift that limit systemically is proposing something with a well-understood downside.
Community reports
The telomerase claim is the central selling point and the cancer tension is essentially never raised alongside it. The Russian literature argues the opposite direction — that epitalon is anti-carcinogenic — and neither position is settled by data anyone else has replicated.
Components carrying the argument: Claimed telomerase activation
Pathophysiology
Ageing is multifactorial, and lifespan studies in humans require decades, large numbers and rigorous controls to detect anything.
Mechanistic rationale
The programme behind this compound published rodent lifespan work and long-running human observational studies of the related preparation epithalamin, reporting reduced mortality. These have not been replicated independently, were not designed to modern randomised standards, and come from the group with an interest in the result. That combination is exactly what independent replication exists to resolve, and it has not happened in several decades of opportunity.
Community reports
Cited widely and confidently in longevity communities. The provenance is rarely examined.
Components carrying the argument: Pineal peptide preparation — mechanism unclear
Pathophysiology
The pineal gland produces melatonin under circadian control, and melatonin output declines with age alongside changes in sleep architecture.
Mechanistic rationale
Epitalon is described as a pineal peptide and is claimed to restore melatonin rhythmicity. This is the most mechanistically modest and therefore the most plausible claim made for it. It is also the one with a trivially cheap and well-studied alternative: melatonin itself, which is inexpensive, orally active and has actual trial data for circadian disorders.
Community reports
Improved sleep is among the most commonly reported effects, alongside vivid dreams.
Components carrying the argument: Claimed pineal and melatonin-axis effects
Pathophysiology
The thymus involutes with age, reducing naive T-cell output and contributing to blunted vaccine responses and infection risk in older adults.
Mechanistic rationale
The bioregulator framing proposes restoration of tissue-specific function including immune competence. The claim is broad and the supporting data is from the same closed literature. Thymosin Alpha-1 occupies the same conceptual space with real approvals and real trials behind it, and it is the better reference point for anyone thinking about this axis.
Community reports
Frequently stacked with other bioregulators on a whole-body-restoration rationale.
Components carrying the argument: Claimed immune restoration
Pathophysiology
Retinitis pigmentosa and other retinal degenerations involve progressive photoreceptor loss.
Mechanistic rationale
The same research tradition produced claims for retinal preparations, and epitalon appears in retinal contexts within it. It is worth noting that Semax holds a genuine Russian registration for optic nerve disease — so the interest in retinal indications within that tradition is not arbitrary. Epitalon has no equivalent registration.
Community reports
Not a common use outside longevity circles.
Components carrying the argument: Claimed tissue-specific regulation
Pathophysiology
Not a condition. A method note, and the most useful item here.
Mechanistic rationale
A body of work from one group over decades is not worthless — BPC-157 has the same structure and this library takes it seriously as a research subject. But single-source evidence is fragile in a specific way: it cannot distinguish a real effect from a systematic methodological quirk, and only independent replication can. For BPC-157 the claims are modest and mechanistically ordinary. For epitalon the claim is lifespan extension, which is the largest claim available, and large claims degrade faster under this weakness rather than slower.
Community reports
Community discussion cites decades of use as evidence. Duration of use is a reason to take a compound seriously as a research subject; it is not a substitute for the replication that has not happened.
Components carrying the argument: —
| Question | Position |
|---|---|
| Approved anywhere? | No — and unlike Semax, not registered in Russia either |
| Independent replication? | Essentially none in several decades |
| Core claim | Telomerase activation and lifespan extension |
| The tension | Telomerase reactivation is a hallmark of most cancers |
| Most plausible claim | Melatonin rhythm — and melatonin is cheap and studied |
| PCAC status | Favourable vote for the 503A Bulks List — not an approval |
| What single-source evidence cannot do | Distinguish a real effect from a systematic quirk |
For healthy ageing, the evidenced list is unglamorous and consistent: not smoking, regular physical activity including resistance training, treating hypertension in midlife, glycaemic control, sleep, maintaining social and cognitive engagement, correcting hearing loss, and vaccination. Every one of those has a larger and better-replicated evidence base than anything marketed as a longevity compound, and several have randomised mortality data.
For sleep and circadian rhythm: melatonin has actual trial evidence for circadian rhythm disorders and jet lag, is inexpensive and orally active. Cognitive behavioural therapy for insomnia is first-line for insomnia itself and outperforms hypnotics at follow-up.
For cancer risk: screening — colorectal, cervical, breast and lung where eligible — detects disease at a stage where treatment works. That is the intervention with the mortality data, and it does not compete with anything on this page.
Physical-chemistry reference for laboratory handling of the lyophilised material. Reproduced so that stability and concentration mathematics can be studied — see the calculator for the arithmetic and the reconstitution guide for sterile technique.
Supplied lyophilised, commonly 10, 50 or 100 mg per vial. A tetrapeptide dissolves readily. At 1 mg daily for a 10-day course, a 10 mg vial is exactly one course — which is why that vial size is standard.
Lyophilised: refrigerated or frozen. Reconstituted: 2–8 °C; short courses mean in-use time is rarely an issue.
Commonly 10 mg, 50 mg and 100 mg lyophilised vials.
Short peptides are comparatively robust; sterility is the governing concern.
Regulatory status changes and differs by country. This is a summary for orientation, not legal advice — check your own jurisdiction.
Not approved as a medicine anywhere. Epithalamin, the pineal extract, has a history of use in the Russian Federation; the synthetic tetrapeptide is sold in the West exclusively as a research chemical.
The regulatory status should not be read as the main caveat here. The main caveat is that the central mechanistic claim — somatic telomerase induction — is either not happening at meaningful levels in vivo, in which case the compound does little, or it is, in which case it warrants far more caution than the longevity framing suggests.
On 23–24 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend Epitalon for inclusion on the Section 503A Bulks List (7–5, one abstention). It was one of six peptides recommended — alongside BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon — out of seven considered.
This followed the FDA's announcement of 15 April 2026 removing twelve peptides from Category 2, the designation for substances judged to raise significant safety concerns. That removal stripped away the basis for enforcement against compounders but did not itself authorise anything, leaving these compounds in a regulatory grey area pending the PCAC review.
A PCAC recommendation is not an approval, and the 503A Bulks List is not a drug approval either. It is also worth knowing that July 2026 was the second round: across two sittings in October and December 2024 the same committee reviewed seven substances — among them ipamorelin, kisspeptin-10, AOD-9604, CJC-1295 and thymosin alpha-1 — and rejected all seven. Two separate things are being conflated in almost every write-up of the 2026 decision:
Regulatory and trial claims re-checked against primary sources on 16 August 2026. Checked: PCAC vote 23-24 July 2026 and the 503A pathway. Approvals, trial readouts and compounding decisions move faster than anything else on this page — a date here means someone looked, not that nothing has changed since.
Athletes subject to WADA, USADA, UKAD, NCAA or military testing should assume any peptide is prohibited unless they have verified otherwise against the current WADA Prohibited List. Several classes here (growth-hormone secretagogues, TB-4 analogues, metabolic modulators) are explicitly named. Check the current list — it is republished annually.
Links resolve to PubMed records, trial registries, publisher pages or primary documents. Where a body of work rather than a single paper is cited, the link opens a PubMed query so the full result set — including newer papers than this page — can be reviewed. Verify every claim against the primary source before relying on it.
For educational and research reference only. Nothing on this site is medical advice, a recommendation, or an instruction to administer any substance to a human being. Every figure on this page is a record of what has been reported, not a recommendation. Full disclaimer.
